Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners
Nuvation Bio to receive $150 million in royalty interest financing and $50 million in debt upon U.S. FDA approval of taletrectinib, with access to additional $50 million in debt at the Company’s option Proceeds from…